Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026...
PR Newswire
More News
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO...
Yahoo! Finance: News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire...
PR Newswire
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, July 6, 2026 ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy failed...
PR Newswire
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors...
Business Wire
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) PR Newswire NEW YORK, June 29, 2026...
PR Newswire
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (ARS or the Company) (NASDAQ: SPRY) for violations of the securities laws.The investigation focuses on whether the Company issued false...
Business Wire
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.
Stocktwits
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage.
Stocktwits
<
1
2
>

Advertisement|Remove ads.